CD8A and cancer: For cancer immunotherapy, and especially a PD-1/PD-L1 blockade where CD8+ T cells should be principal effector cells, such an immunoscore could also be a predictive factor because infiltrating CD8+ T lymphocytes are a marker of a pre-existing immunity that can be released from immunosuppression by a PD-1/PD-L1 blockade.